KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) EBT (2016 - 2025)

AbbVie (ABBV) has disclosed EBT for 14 consecutive years, with $2.7 billion as the latest value for Q4 2025.

  • Quarterly EBT rose 217.58% to $2.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 billion through Dec 2025, up 77.53% year-over-year, with the annual reading at $6.6 billion for FY2025, 77.53% up from the prior year.
  • EBT for Q4 2025 was $2.7 billion at AbbVie, up from $714.0 million in the prior quarter.
  • The five-year high for EBT was $4.9 billion in Q1 2022, with the low at -$2.3 billion in Q4 2024.
  • Average EBT over 5 years is $2.2 billion, with a median of $2.0 billion recorded in 2023.
  • The sharpest move saw EBT soared 383.41% in 2021, then plummeted 287.21% in 2024.
  • Over 5 years, EBT stood at $4.3 billion in 2021, then tumbled by 30.58% to $3.0 billion in 2022, then tumbled by 59.12% to $1.2 billion in 2023, then tumbled by 287.21% to -$2.3 billion in 2024, then surged by 217.58% to $2.7 billion in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $2.7 billion, $714.0 million, and $1.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.